Lactosaminated human albumin, a hepatotropic carrier of drugs

European Journal of Pharmaceutical Sciences

Volumn 40, Issue 4, 2010, Pages 253-262

  Fiume, Luigi ^a   Di Stefano, Giuseppina ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Hepatocellular carcinoma; Liver micrometastases; Liver targeting of drugs; Viral hepatitis

Indexed keywords

ASIALOGLYCOPROTEIN RECEPTOR; DOXORUBICIN; DRUG CARRIER; FLOXURIDINE; FLUOROURACIL; LACTOSAMINATED HUMAN ALBUMIN; UNCLASSIFIED DRUG; VIDARABINE; VIDARABINE PHOSPHATE; ALB PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; GLYCOPROTEIN; LACTOSAMINATED SERUM ALBUMIN; SERUM ALBUMIN;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLON CANCER; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER SINUSOID; MYALGIA; NEUROTOXICITY; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; SENSORY NEUROPATHY; VIRUS INHIBITION; VIRUS REPLICATION; WOODCHUCK HEPATITIS; ANIMAL; DRUG EFFECTS; LIVER; METABOLISM; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; ASIALOGLYCOPROTEIN RECEPTOR; DOXORUBICIN; DRUG CARRIERS; FLOXURIDINE; GLYCOPROTEINS; HUMANS; LIVER; SERUM ALBUMIN; TISSUE DISTRIBUTION; VIDARABINE PHOSPHATE;

EID: 77955684788     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2010.04.004     Document Type: Review

References (86)

1. Andrews J.C., Kunsten C., Terio P., Priescorn D., Ensminger W. Hepatobiliary toxicity of 5-fluoro-2'-deoxyuridine. Intra-arterial versus portal venous routes of infusion. Invest. Radiol. 1991, 26:461-464.
2. Ashwell G., Morell A.G. The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. Adv. Enzymol. 1974, 41:99-128.
3. Baddiley J., Buchanan J.G., Letters R. Phosphorylation through glyoxalines [imidazolides] and its significance in enzymic transphosphorylation. J. Chem. Soc. 1956, 2812-2817.
4. Baglioni M., Fiume L., Bolondi L., Farina C., Kratz F., Di Stefano G. Binding of the doxorubicin-lactosaminated human albumin conjugate to HCC cells is mediated by the drug moieties. Dig. Liver Dis. 2008, 40:963-964.
5. Bijsterbosch M.K., Schouten D., van Berkel T.J.C. Synthesis of dioleoyl derivative of iododeoxyuridine and its incorporation into reconstituted high density lipoprotein particles. Biochemistry 1994, 33:14073-14080.
6. 13C NMR spectroscopy. Eur. J. Pharm. Sci. 2009, 38:262-269.
7. Borch R.F., Bernstein M.D., Durst H.D. The cyanohydroborate anion as a selective reducing agent. J. Am. Chem. Soc. 1971, 93:2897-2904.
8. Chadwick R.G., Bassendine M.F., Crawford E.M., Thomas H.C., Sherlock S. HBsAg-positive chronic liver disease: inhibition of DNA polymerase activity by vidarabine. Br. Med. J. 1978, 2:531-533.
9. Cho K.J., Lunderquist A. The peribiliary vascular plexus: the microvascular architecture of the bile duct in the rabbit and in clinical cases. Radiology 1983, 147:357-364.
10. Di Sabato G., Jencks W.P. Mechanism and catalysis of reactions of acyl phosphates. I. Nucleophilic reactions. J. Am. Chem. Soc. 1961, 83:4393-4400.
11. Di Stefano G., Busi C., Fiume L. Floxuridine coupling with lactosaminated human albumin to increase the drug efficacy on liver micrometastases. Dig. Liver Dis. 2002, 34:439-446.
12. Di Stefano G., Busi C., Camerino A., Nardo B., Fiume L. Enhanced liver blood concentrations of adenine arabinoside accomplished by lactosaminated poly-l-lysine coupling: implications for regional chemotherapy of hepatic micrometastases. Biochem. Pharmacol. 2000, 61:457-463.
13. 3H]thymidine incorporation into DNA of rat regenerating liver by 2',2'-difluorodeoxycytidine coupled to lactosaminated poly-l-lysine. Biochem. Pharmacol. 1999, 57:793-799.
14. Di Stefano G., Busi C., Mattioli A., Fiume L. Selective delivery to the liver of antiviral nucleoside analogs coupled to a high molecular mass lactosaminated poly-l-lysine and administered to mice by intramuscular route. Biochem. Pharmacol. 1995, 49:1769-1775.
15. Di Stefano G., Colonna F.P., Bongini A., Busi C., Mattioli A., Fiume L. Ribavirin conjugated with lactosaminated poly-l-lysine. Selective delivery to the liver and increased antiviral activity in mice with viral hepatitis. Biochem. Pharmacol. 1997, 54:357-363.
16. Di Stefano G., Derenzini M., Kratz F., Lanza M., Fiume L. Liver targeted doxorubicin: effects on regenerating rat hepatocytes. Liver Int. 2004, 24:246-252.
17. Di Stefano G., Fiume L., Baglioni M., Bolondi L., Busi C., Chieco P., Kratz F., Manaresi F., Pariali M. A conjugate of doxorubicin with lactosaminated albumin enhances the drug concentrations in all the forms of rat hepatocellular carcinomas independently of their differentiation grade. Liver Int. 2006, 26:726-733.
18. Di Stefano G., Fiume L., Baglioni M., Bolondi L., Chieco P., Kratz F., Pariali M., Rubini G. Efficacy of doxorubicin coupled to lactosaminated albumin on rat HCCs evaluated by ultrasound imaging. Dig. Liver Dis. 2008, 40:278-284.
19. Di Stefano G., Fiume L., Baglioni M., Busi C., Bolondi L., Farina C., Mori F., Chieco P., Pariali M., Kratz F., Molin L., Salmaso S., Caliceti P. Doxorubicin coupled to lactosaminated albumin: effect of heterogeneity in drug load on conjugate disposition and hepatocellular carcinoma uptake in rats. Eur. J. Pharm. Sci. 2008, 33:191-198.
20. Di Stefano G., Fiume L., Baglioni M., Busi C., Chieco P., Kratz F., Mattioli A. Coupling of lactose molecules to the carrier protein hinders the spleen and bone marrow uptake of doxorubicin conjugated with human albumin. Eur. J. Pharm. Sci. 2007, 30:136-142.
21. Di Stefano G., Fiume L., Bolondi L., Lanza M., Pariali M., Chieco P. Enhanced uptake of lactosaminated human albumin by rat hepatocarcinomas: implications for an improved chemotherapy of primary liver tumors. Liver Int. 2005, 25:854-860.
22. Di Stefano G., Fiume L., Domenicali M., Busi C., Chieco P., Kratz F., Lanza M., Mattioli A., Pariali M., Bernardi M. Doxorubicin coupled to lactosaminated albumin: effects on rats with liver fibrosis and cirrhosis. Dig. Liver Dis. 2006, 38:404-408.
23. Di Stefano G., Kratz F., Lanza M., Fiume L. Doxorubicin coupled to lactosaminated human albumin remains confined within mouse liver cells after the intracellular release from the carrier. Dig. Liver Dis. 2003, 35:428-433.
24. Di Stefano G., Lanza M., Busi C., Barbieri L., Fiume L. Conjugates of nucleoside analogs with lactosaminated human albumin to selectively increase the drug levels in liver blood: requirements for a regional chemotherapy. J. Pharm. Exp. Ther. 2002, 301:638-642.
25. Di Stefano G., Lanza M., Kratz F., Merina L., Fiume L. A novel method for coupling doxorubicin to lactosaminated human albumin by an acid sensitive hydrazone bond: synthesis, characterization and preliminary biological properties of the conjugate. Eur. J. Pharm. Sci. 2004, 23:393-397.
26. Di Stefano G., Tubaro M., Lanza M., Boga C., Fiume L., Traldi P. Synthesis and physicochemical characterisitcs of a liver-targeted conjugate of fluorodeoxyuridine monophosphate with lactosaminated human albumin. Rapid Commun. Mass Spectrom. 2003, 17:2503-2507.
27. Ensminger W.D., Gyves J.W. Regional chemotherapy of neoplastic diseases. Pharmacol. Ther. 1983, 21:277-293.
28. Ensminger W.D., Rosowsky A., Raso V., Levin D.C., Glode M., Come S., Steele G., Frei E. A clinical-pharmacological evaluation of hepatic arterial infusion of 5-fluoro 2'-deoxyuridine and 5-fluorouracil. Cancer Res. 1978, 38:3784-3792.
29. Fielding L.P., Hittinger R., Grace R.H., Fry J.S. Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma. Lancet 1992, 340:502-506.
30. Fiume L. Penetration of β-amanitin-rabbit-albumin conjugate into hepatic parenchymal cells. Lancet 1969, 2:853-854.
31. Fiume L., Bassi B., Bongini A. Conjugates of 9-β-d-arabinofuranosyladenine 5'-monophosphate (ara-AMP) with lactosaminated albumin: characterization of the drug-carrier bonds. Pharm. Acta Helv. 1988, 63:137-139.
32. Fiume L., Bassi B., Busi C., Mattioli A. Preparation of lactosaminated albumin-ara-AMP conjugate which remains soluble after lyophilization. Pharm. Acta Helv. 1985, 60:318-320.
33. Fiume L., Bassi B., Busi C., Mattioli A., Spinosa G. Drug targeting in antiviral chemotherapy. A chemically stable conjugate of 9-β-d-arabinofuranosyladenine 5'-monophosphate with lactosaminated albumin accomplishes a selective delivery of the drug to liver cells. Biochem. Pharmacol. 1986, 35:967-972.
34. Fiume L., Betts C.M., Busi C., Corzani S., Derenzini M., Di Stefano G., Mattioli A. The pathogenesis of vacuoles produced in rat and mouse liver cells by a conjugate of adenine arabinoside monophosphate with lactosaminated albumin. J. Hepatol. 1992, 15:314-322.
35. Fiume L., Bolondi L., Busi C., Chieco P., Kratz F., Lanza M., Mattioli A., Di Stefano G. Doxorubicin coupled to lactosaminated albumin inhibits the growth of hepatocellular carcinomas induced in rats by diethylnitrosamine. J. Hepatol. 2005, 43:645-652.
36. Fiume L., Busi C., Corzani S., Di Stefano G., Gervasi G.B., Mattioli A. Organ distribution of a conjugate of adenine arabinoside monophosphate with lactosamianted albumin in the rat. J. Hepatol. 1994, 20:681-682.
37. Fiume L., Busi C., Di Stefano G., Mattioli A. Coupling of antiviral nucleoside analogs to lactosaminated human albumin by using the imidazolides of their phosphoric esters. Anal. Biochem. 1993, 212:407-411.
38. Fiume L., Busi C., Mattioli A. Lactosaminated human serum albumin as hepatotropic drug carrier. Rate of uptake by mouse liver. FEBS Lett. 1982, 146:42-46.
39. Fiume L., Busi C., Mattioli A., Balboni P.G., Barbanti-Brodano G. Hepatocyte targeting of adenine-9-β-d-arabinofuranoside 5'-monophosphate (ara-AMP) coupled to lactosaminated albumin. FEBS Lett. 1981, 129:261-264.
40. Fiume L., Busi C., Preti P., Spinosa G. Conjugates of ara-AMP with lactosaminated albumin: a study on their immunogenicity in mouse and rat. Cancer Drug Deliv. 1987, 4:145-150.
41. Fiume L., Campadelli Fiume G., Wieland T. Facilitated penetration of amanitin-albumin conjugates into hepatocytes after coupling with fluorescein. Nat. New Biol. 1971, 230:219-220.
42. Fiume L., Mattioli A., Balboni P.G., Tognon M., Barbanti-Brodano G., De Vries J., Wieland T. Enhanced inhibiton of virus DNA synthesis in hepatocytes by trifluorothymidine coupled to asialofetuin. FEBS Lett. 1979, 103:47-51.
43. Fiume L., Mattioli A., Busi C., Balboni P.G., Barbanti-Brodano G., De Vries J., Altman L., Wieland T. Selective inhibition of Ectromelia virus DNA synthesis in hepatocytes by adenine-9-β-d-arabinofuranoside (ara-A) and adenine-9-β-d-arabinofuranoside 5'-monophosphate (ara-AMP) conjugated to asialofetuin. FEBS Lett. 1980, 116:185-188.
44. Fiume L., Mattioli A., Busi C., Spinosa G., Wieland T. Conjugtes of adenine-9-β-d-arabinofuranoside monophosphate (ara-AMP) with lactosaminated homologous albumin are not immunogenic in the mouse. Experientia 1982, 38:1087-1089.
45. Fiume L., Torrani Cerenzia M.R., Bonino F., Busi C., Mattioli A., Brunetto M.R., Chiaberge E., Verme G. Inhibition of hepatitis B virus replication by vidarabine monophosphate conjugated with lactosaminated serum albumin. Lancet 1988, 2:13-15.
46. Goormaghtigh E., Chatelain P., Caspers J., Ruysschaert J.M. Evidence of a specific complex between adriamycin and negatively-charged phospholipids. Biochym. Biophys. Acta 1980, 597:1-14.
47. Gray G.R. The direct coupling of oligosaccharides to proteins and derivatized gels. Arch. Biochem. Biophys. 1974, 163:426-428.
48. Greenfield R.S., Kaneko T., Daues A., Edson M.A., Fitzgerald K.A., Olech L.J., Grattan J.A., Spitalny G.L., Braslawsky G.R. Evaluation in vitro of adriamycin immunoconjugates synthesized using an acid-sensitive hydrazone linker. Cancer Res. 1990, 50:6600-6607.
49. Groman E.V., Enriquez P.M., Jung C., Josephson L. Arabinogalactan for hepatic drug delivery. Bioconj. Chem. 1994, 5:547-556.
50. Halloran M.J., Parker C.W. The preparation of nucleotide protein conjugates: carbodiimides as coupling agents. J. Immunol. 1966, 96:373-378.
51. Harris L., Preat V., Farber E. Patterns of ligand binding to normal, regenerating, preneoplastic, and neoplastic rat hepatocytes. Cancer Res. 1987, 47:3954-3958.
52. Hoare D.G., Koshland D.E. A method for the quantitative modification and estimationof carboxylic acid groups in proteins. J. Biol. Chem. 1967, 242:2447-2453.
53. Hohn D.C., Melnick J., Stagg R., Altman D., Ignoffo R., Ferrell L., Lewis B. Biliary sclerosis in patients receiving hepatic arterial infusion of floxuridine. J. Clin. Oncol. 1985, 3:98-102.
54. Hoofnagle J.H., Hanson R.G., Minuk G.Y., Pappas S.C., Schafer D.F., Dusheiko G.M., Straus S.E., Popper H., Jones E.A. Randomized controlled trial of adenine arabinoside monophosphate for chronic type B hepatitis. Gastroenterology 1984, 86:150-157.
55. Kemeny N., Seiter K., Niedzwiecki D., Chapman D., Sigurdson E., Cohen A., Botet J., Oderman P., Murray P. A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer 1992, 69:327-334.
56. Kopecek J., Kopeckova P. HPMA copolymers: origins, early developments, present, and future. Adv. Drug Deliv. Rev. 2010, 62:122-149.
57. Krantz M.J., Holtzman N.A., Stowell C.P., Lee Y.C. Attachment of thioglycoside to proteins: enhancement of liver membrane binding. Biochemistry 1976, 15:3963-3968.
58. Llovet J.M., Burroughs A., Bruix J. Hepatocellular carcinoma. Lancet 2003, 367:1907-1917.
59. Lohrmann R., Orgel R.E. Preferential formation of (2'-5')-linked internucleotide bonds in non-enzymatic reactions. Tetrahedron 1978, 34:853-855.
60. MacDonald J.S., Astrow A.B. Adjuvant therapy of colon cancer. Semin. Oncology 2001, 28:30-40.
61. Mitra S.K. The terminal distribution of hepatic artery with special reference to arterio-portal anastomosis. J. Anat. 1966, 100:651-663.
62. O'Hare K.B., Hume I.C., Scarlett L., Chytry V., Kopeckova P., Kopecek J., Duncan R. Effect of galactose on interaction of N-(2-hydroxypropyl) metacrylamide copolymers with hepatoma cells in culture: preliminary applications to an anticancer agents, daunomycin. Hepatology 1989, 10:207-214.
63. Pollard R.B., Smith J.L., Neal E.A., Gregory P.B., Merigan T.C., Robinson W.S. Effect of vidarabine on chronic hepatitis B virus infection. J. Am. Med. Assoc. 1978, 239:1648-1650.
64. Pontisso P., Poon M.C., Tiollais P., Brechot C. Detection of hepatitis B virus in mononuclear blood cells. Br. Med J. 1984, 288:1563-1566.
65. Ponzetto A., Fiume L., Forzani B., Song S.Y., Busi C., Mattioli A., Spinelli C., Marinelli M., Smedile A., Chiaberge E., Bonino F., Gervasi G.B., Rapicetta M., Verme G. Adenine arabinoside monophosphate and acyclovir monophosphate coupled to lactosaminated albumin reduce woodchuck hepatitis virus viremia at doses lower than do the unconjugated drugs. Hepatology 1991, 14:16-24.
66. Rappaport A.M. The microcirculatory hepatic unit. Microvasc. Res. 1973, 6:212-228.
67. Rogers J.C., Kornfeld S. Hepatic uptake of proteins coupled to fetuin glycopeptide. Biochem. Biophys. Res. Commun. 1971, 45:622-629.
68. Romet-Lemonne J.P., McLane M.F., Elfassi E., Haseltine W.A., Azocar J., Essex M. Hepatitis virus infection in cultured human lymphoblastoid cells. Science 1983, 221:667-669.
69. Rougier P., Sahmoud T., Nitti D., Curran D., Doci R., De Waele B., Nakajima T., Rauschecker H., Labianca R., Pector J.C., Marsoni S., Apolone G., Lasser P., Couvreur M.L., Wils J. Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. Lancet 1998, 351:1677-1681.
70. Schneider Y., Abarca J., Aboud-Pirak E., Baurain R., Ceulemans F., Deprez-De Campeneere D., Lesur B., Masquelier M., Otte-Slachmuylder C., Rolin-van Swieten D., Trouet A. Drug targeting in human cancer chemotherapy. Receptor-Mediated Targeting of Drugs, NATO ASI Series A: Life Sciences 1984, vol. 82:1-25. Plenum Press, New York.
71. Schwartz B.A., Gray G.R. Proteins containing reductively aminated disaccharides. Synthesis and chemical characterization. Arch. Biochem. Biophys. 1977, 181:542-549.
72. Seymour L.W., Ferry D.R., Anderson D., Hesslewood S., Julyan P.J., Poyner R., Doran J., Young A.M., Burtles S., Kerr D.J. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J. Clin. Oncol. 2002, 20:1668-1676.
73. Sheehan J.C., Hlavka J.J. The cross-linking of gelatin using a water-soluble carbodiimide. J. Am. Chem. Soc. 1957, 79:4528-4529.
74. Staab H.A., Scaller H., Cramer F. An imidazolide of phosphoric acid. Angew. Chem. 1959, 71:736.
75. Taylor I., Machin D., Mullee M., Trotter G., Cooke T., West C. A randomised controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer. Br. J. Surg. 1985, 72:359-363.
76. Torrani Cerenzia M., Fiume L., De Bernardi Venon W., Lavezzo B., Brunetto M.R., Ponzetto A., Di Stefano G., Busi C., Mattioli A., Gervasi G.B., Bonino F., Verme G. Adenine arabinoside monophosphate coupled to lactosamianted human albumin administered for 4 weeks in patients with chronic type B hepatitis decreased viremia without producing significant side effects. Hepatology 1996, 23:657-661.
77. Torrani Cerenzia M.R., Fiume L., Busi C., Mattioli A., Di Stefano G., Gervasi G.B., Brunetto M.R., Piantino P., Verme G. Inhibition of hepatitis B virus replication by adenine arabinoside monophosphate coupled to lactosamianted albumin. Efficacy and minimal active dose. J. Hepatol. 1994, 20:307-309.
78. Trerè D., Fiume L., Badiali De Giorgi L., Di Stefano G., Migaldi M., Derenzini M. The asialoglycoprotein receptor in human hepatocellular carcinomas. Its expression on the proliferating cells. Br. J. Cancer 1999, 81:404-408.
79. van Laar J.A.M., Rustum Y.M., Ackland S.P., van Groeningen C.J., Peters G.J. Comparison of 5-fluoro-2'-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer. Eur. J. Cancer 1998, 34:296-306.
80. Wagner J.G., Gyves J.W., Stetson P.L., Walker-Andrews S.C., Wollner I.S., Cochran M.K., Ensminger W.D. Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients. Cancer Res. 1986, 46:1499-1506.
81. Weller I.V.D., Bassendine M.F., Craxi A., Fowler M.J.F., Monjardino J., Thomas H.C., Sherlock S. Successful treatment of HBs and HBeAg positive chronic liver disease: prolonged inhibition of viral replication by highly soluble adenine arabinoside 5'-monophosphate (ara-AMP). Gut 1982, 23:717-723.
82. Willner D., Trail P.A., Hofstead S.J., King H.D., Lasch S.J., Braslawsky G.R., Greenfield R.S., Kaneko K., Firestone R.A. (6-Maleimidocaproyl)hydrazone derivative of doxorubicin-a new derivative for the preparation of immunoconjugates of doxorubicin. Bioconjug. Chem. 1993, 4:521-527.
83. Wilson G. Effect of reductive lactosamination on the hepatic uptake of bovine pancreatic ribonuclease A dimer. J. Biol. Chem. 1978, 253:2070-2072.
84. Yeo W., Mok T.S., Zee B., Leung T.W.T., Lai P.B.S., Lau W.Y., Koh J., Mo F.K.F., Yu S.C.H., Chan A.T., Hui P., Ma P., Lam K.C., Ho W.M., Wong H.T., Tang A., Johnson P.J. A randomized phase III study of doxorubicin versus cisplatin/interferon α-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J. Natl. Cancer Inst. 2005, 97:1532-1538.
85. Yoshikawa M., Kato T., Takeshini T. A novel method for phosphorylation of nucleosides to 5'-nucleotides. Tetrahedron Lett. 1967, 50:5065-5068.
86. Zarski J.P., Barange K., Souvignet C., Bertini M., Marcellin P., Tran A., Deugnier Y., Couzigou P., Plages A., Ambroise-Thomas P. Efficacy and safety of lactosaminated human serum albumin-adenine arabinoside monophosphate in chronic hepatitis B patients non-responders to interferon therapy: a randomised clinical trial. J. Hepatol. 2001, 34:487-488.